Sarcopenia in Children With End‐Stage Liver Disease on the Transplant Waiting List

• Published in: Liver transplantation Vol. 27; no. 5; pp. 641 - 651
• Main Authors: Woolfson, Jessica P., Perez, Manuela, Chavhan, Govind B., Johara, Fatema T., Lurz, Eberhard, Kamath, Binita M., Ng, Vicky L.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2021; John Wiley and Sons Inc
• Subjects: Adult; Child; Child, Preschool; Children; Computed tomography; End Stage Liver Disease - complications; End Stage Liver Disease - surgery; Female; Growth curves; Humans; Liver diseases; Liver transplantation; Liver Transplantation - adverse effects; Male; Morbidity; Mortality; Nutritional status; Original; Pediatrics; Psoas muscle; Retrospective Studies; Sarcopenia; Sarcopenia - complications; Sarcopenia - diagnostic imaging; Sarcopenia - epidemiology; Transplants & implants; Waiting Lists
• ISSN: 1527-6465; 1527-6473
• DOI: 10.1002/lt.25985

Sarcopenia predicts morbidity and mortality in adults with end‐stage liver disease (ESLD) and is determined by total psoas muscle area (tPMA) measurement from computed tomography (CT) imaging. Recently developed pediatric age‐ and sex‐specific tPMA growth curves provide the opportunity to ascertain prevalence and impact of sarcopenia in children awaiting liver transplantation (LT). This retrospective single‐center study evaluated sarcopenia in children between 1 and 16 years with ESLD and a clinically indicated abdominal CT less than 3 months before first isolated LT. Sarcopenia was defined as tPMA z score less than −2 measured at the intervertebral L4‐5 level. Patient demographic, biochemical, and outcome data were recorded. tPMA was compared with other measures of nutritional status using univariate and multivariate logistic analyses. Outcome measures included 1‐year morbidity events and mortality after LT. CT images from 25 (64% female) children with median age of 5.50 (interquartile range [IQR], 3.75‐11.33) years were reviewed. Ten children (40%) had a tPMA z score less than −2. Sarcopenia was associated with lower z scores for weight (odds ratio [OR], 0.38; P = 0.02), height (OR, 0.32; P = 0.03), and nutritional support before LT (OR, 12.93; P = 0.01). Sarcopenic children had a longer duration of pediatric intensive care unit (PICU) stay (3.50 [IQR, 3.00‐6.00] versus 2.00 [IQR, 2.00‐3.50] days; P = 0.03). Sarcopenia was prevalent in 40% of children with ESLD awaiting LT, and lower tPMA z score was associated with deficient anthropometrics and need for nutritional support before LT. Post‐LT PICU duration was increased in children with sarcopenia, reflecting adverse outcomes associated with muscle loss. Further studies are needed to elucidate the underlying mechanisms of sarcopenia in children with ESLD.